A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer

BACKGROUND. This study aimed to characterize the neurotoxicity of three different regimens of nab‐paclitaxel compared with a standard regimen of solvent‐based (sb) paclitaxel for the first‐line treatment of HER2‐negative metastatic breast cancer based on the Total Neurotoxicity Score (TNS), a tool s...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Ciruelos, Eva, Apellániz‐Ruiz, María, Cantos, Blanca, Martinez‐Jáñez, Noelia, Bueno‐Muiño, Coralia, Echarri, Maria‐Jose, Enrech, Santos, Guerra, Juan‐Antonio, Manso, Luis, Pascual, Tomas, Dominguez, Cristina, Gonzalo, Juan‐Francisco, Sanz, Juan‐Luis, Rodriguez‐Antona, Cristina, Sepúlveda, Juan‐Manuel
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2019
Témata:
Breast Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853092/
https://ncbi.nlm.nih.gov/pubmed/31023863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0664
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky